Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China Clinical Cure Project for Chronic Hepatitis B
ChiCTR1800020369Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (3 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: HBsAg negative conversion rate at 96 weeks and HBsAg seroconversion rate at 96 weeks. Started Dec 2018; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1800020369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020369.